Last reviewed · How we verify
Secondary progressive multiple sclerosis
Approved treatments
- Arzerra · Glaxo Grp Ltd
Arzerra works by binding to the CD20 protein on B cells, marking them for destruction by the immune system. - Mayzent · Novartis Pharmaceuticals
- Mayzent · Novartis
Mayzent works by binding to the sphingosine 1-phosphate receptor 1, which helps to reduce inflammation and slow disease progression. - Arzerra · GlaxoSmithKline
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Secondary progressive multiple sclerosis patent landscape — cliff calendar, originator estates, attackable patents
- Secondary progressive multiple sclerosis treatment landscape brief
- Secondary progressive multiple sclerosis treatment updates RSS
Frequently asked questions about Secondary progressive multiple sclerosis
What drugs treat Secondary progressive multiple sclerosis?
Tracked treatments include Arzerra, Mayzent.
What is the treatment for Secondary progressive multiple sclerosis?
Standard treatment for Secondary progressive multiple sclerosis includes Arzerra, Mayzent. See the treatment landscape page for first-line, second-line and salvage options.
Related
- Treatment landscape: Secondary progressive multiple sclerosis patent cliff · Secondary progressive multiple sclerosis CI report
- Treatment: Arzerra · Glaxo Grp Ltd
- Treatment: Mayzent · Novartis Pharmaceuticals
- Treatment: Mayzent · Novartis
- Treatment: Arzerra · GlaxoSmithKline
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing